Adenosine A(2A) receptor mRNA expression in Parkinson's disease

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• The adenosine A(2A) receptor is implicated in basal ganglia function.
• Dysregulation of neurotransmitter systems is observed in Parkinson's disease.

Purpose of the Study:

• To investigate adenosine A(2A) receptor mRNA expression in post-mortem human brain tissue from Parkinson's disease patients and controls.
• To determine if dopaminergic drug treatment affects adenosine A(2A) receptor mRNA levels.

Main Methods:

• Reverse transcription polymerase chain reaction (RT-PCR) was used to quantify adenosine A(2A) receptor mRNA.
• Post-mortem brain tissue from normal subjects and Parkinson's disease patients was analyzed.
• Specific brain regions including striatal and extrastriatal areas were examined.

Main Results:

• Adenosine A(2A) receptor mRNA was detected in both striatal and extrastriatal regions.
• A significant decrease in mRNA levels was observed in the caudate nucleus and putamen of Parkinsonian brains.
• A significant increase in mRNA levels was found in the substantia nigra pars reticulata of Parkinsonian brains.
• No significant changes were observed in other brain regions.

Conclusions:

• Adenosine A(2A) receptor mRNA expression is altered in the basal ganglia of Parkinson's disease patients.
• The adenosine A(2A) receptor is subject to regulation by dopaminergic systems in the human brain.
• The adenosine A(2A) receptor represents a potential therapeutic target for basal ganglia disorders like Parkinson's disease.